QQQ   424.69 (-0.27%)
AAPL   168.40 (+0.24%)
MSFT   409.04 (-0.68%)
META   502.66 (+1.72%)
GOOGL   154.86 (-0.39%)
AMZN   180.99 (-0.16%)
TSLA   149.07 (-4.10%)
NVDA   841.83 (+0.18%)
AMD   154.76 (+0.48%)
NIO   3.86 (-1.28%)
BABA   69.07 (+0.36%)
T   16.13 (+0.06%)
F   12.03 (-0.08%)
MU   116.10 (-0.20%)
GE   157.24 (+1.01%)
CGC   6.43 (-0.92%)
DIS   113.25 (+0.27%)
AMC   2.80 (-6.04%)
PFE   25.34 (-0.31%)
PYPL   62.94 (-0.51%)
XOM   118.42 (-0.18%)
QQQ   424.69 (-0.27%)
AAPL   168.40 (+0.24%)
MSFT   409.04 (-0.68%)
META   502.66 (+1.72%)
GOOGL   154.86 (-0.39%)
AMZN   180.99 (-0.16%)
TSLA   149.07 (-4.10%)
NVDA   841.83 (+0.18%)
AMD   154.76 (+0.48%)
NIO   3.86 (-1.28%)
BABA   69.07 (+0.36%)
T   16.13 (+0.06%)
F   12.03 (-0.08%)
MU   116.10 (-0.20%)
GE   157.24 (+1.01%)
CGC   6.43 (-0.92%)
DIS   113.25 (+0.27%)
AMC   2.80 (-6.04%)
PFE   25.34 (-0.31%)
PYPL   62.94 (-0.51%)
XOM   118.42 (-0.18%)
QQQ   424.69 (-0.27%)
AAPL   168.40 (+0.24%)
MSFT   409.04 (-0.68%)
META   502.66 (+1.72%)
GOOGL   154.86 (-0.39%)
AMZN   180.99 (-0.16%)
TSLA   149.07 (-4.10%)
NVDA   841.83 (+0.18%)
AMD   154.76 (+0.48%)
NIO   3.86 (-1.28%)
BABA   69.07 (+0.36%)
T   16.13 (+0.06%)
F   12.03 (-0.08%)
MU   116.10 (-0.20%)
GE   157.24 (+1.01%)
CGC   6.43 (-0.92%)
DIS   113.25 (+0.27%)
AMC   2.80 (-6.04%)
PFE   25.34 (-0.31%)
PYPL   62.94 (-0.51%)
XOM   118.42 (-0.18%)
QQQ   424.69 (-0.27%)
AAPL   168.40 (+0.24%)
MSFT   409.04 (-0.68%)
META   502.66 (+1.72%)
GOOGL   154.86 (-0.39%)
AMZN   180.99 (-0.16%)
TSLA   149.07 (-4.10%)
NVDA   841.83 (+0.18%)
AMD   154.76 (+0.48%)
NIO   3.86 (-1.28%)
BABA   69.07 (+0.36%)
T   16.13 (+0.06%)
F   12.03 (-0.08%)
MU   116.10 (-0.20%)
GE   157.24 (+1.01%)
CGC   6.43 (-0.92%)
DIS   113.25 (+0.27%)
AMC   2.80 (-6.04%)
PFE   25.34 (-0.31%)
PYPL   62.94 (-0.51%)
XOM   118.42 (-0.18%)
Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)
Free ALPMY Stock Alerts
$9.46
+0.12 (+1.28%)
(As of 04/17/2024 ET)
Compare
Today's Range
$9.22
▼
$9.50
50-Day Range
$9.27
▼
$11.15
52-Week Range
$9.15
▼
$16.91
Volume
502,581 shs
Average Volume
319,958 shs
Market Capitalization
$17.12 billion
P/E Ratio
23.95
Dividend Yield
3.59%
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest
ALPMY stock logo

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMY Stock Price History

ALPMY Stock News Headlines

April 15, 2024 | finance.yahoo.com
U.S. Stocks Erase Early Gains
April 15, 2024 | finance.yahoo.com
Stocks Lose Steam to Start Week; Goldman Rises After Earnings
April 18, 2024 | Darwin (Ad)
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
April 15, 2024 | finance.yahoo.com
Stock Futures Up With Goldman Earnings in Focus
April 12, 2024 | americanbankingnews.com
Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 53.1% in March
April 4, 2024 | morningstar.com
Astellas Pharma Inc ADR
March 29, 2024 | msn.com
China NMPA accepts Astellas’ sBLA for urothelial cancer treatment
March 28, 2024 | markets.businessinsider.com
Astellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In China
April 18, 2024 | Darwin (Ad)
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
March 28, 2024 | finance.yahoo.com
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
March 26, 2024 | finanznachrichten.de
Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
March 26, 2024 | finanznachrichten.de
Astellas Pharma Receives Permanent J-code for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
March 26, 2024 | finance.yahoo.com
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
March 26, 2024 | finance.yahoo.com
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
March 22, 2024 | prnewswire.com
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
March 20, 2024 | finance.yahoo.com
Q4 2023 Taysha Gene Therapies Inc Earnings Call
March 11, 2024 | finance.yahoo.com
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
March 11, 2024 | businesswire.com
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
March 3, 2024 | prnewswire.com
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
February 15, 2024 | finance.yahoo.com
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
February 15, 2024 | finance.yahoo.com
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
February 15, 2024 | prnewswire.com
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
February 7, 2024 | finance.yahoo.com
Astellas Makes Announcement about Management Structure
February 1, 2024 | finance.yahoo.com
Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
January 31, 2024 | markets.businessinsider.com
Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment
January 31, 2024 | markets.businessinsider.com
Astellas Pharma Announces Collaboration With Mass General Brigham
January 31, 2024 | finance.yahoo.com
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
See More Headlines
Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
4/17/2024
Fiscal Year End
3/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
CUSIP
N/A
CIK
1446390
Web
www.astellas.com
Phone
(133) 244-3000
Fax
N/A
Employees
14,484
Year Founded
1923

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
23.77
Forward P/E Ratio
27.03
P/E Growth
1.24
Net Income
$742 million
Net Margins
0.08%
Pretax Margin
N/A
Return on Equity
6.39%
Return on Assets
3.29%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
0.91
Quick Ratio
0.71

Sales & Book Value

Annual Sales
$11.24 billion
Price / Sales
1.52
Cash Flow
$1.39 per share
Price / Cash Flow
6.83
Book Value
$6.27 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$17.12 billion
Optionable
Not Optionable
Beta
0.32

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover
The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Naoki Okamura BSc (Age 62)
    President, CEO & Director
    Comp: $961.41k
  • Mr. Atsushi Kitamura
    Chief Financial Officer
  • Nobue Yasuda
    General Manager of Finance & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Senior Managing Executive Officer
  • Ms. Catherine B. Levitt
    General Counsel
  • Mr. Katsuyoshi Sugita (Age 57)
    Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
  • Mr. Stig Ogata
    Vice President of Corporate Communications
  • Ms. Collette Taylor (Age 61)
    Senior Vice President of Human Resources
  • Ms. Tatjana Dragovic
    Senior VP and Head of Ethics & Compliance
  • Mr. Nobuaki Tanaka
    President of Japan Commercial & Senior Corporate Executive

Key Competitors

View All Competitors

Should I Buy Astellas Pharma Stock? ALPMY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

  • Astellas Pharma Inc. has a diverse portfolio of pharmaceutical products, including XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, and PADCEV for urothelial cancer, which can provide stable revenue streams.
  • The company has shown resilience in the market with a market capitalization of $19.45 billion, indicating a strong presence and stability in the industry.
  • Astellas Pharma's recent quarterly earnings report showed a positive EPS of $0.12, demonstrating financial growth and potential for investors.
  • With a low debt-to-equity ratio of 0.31, Astellas Pharma has a healthy balance sheet, reducing financial risk for investors.
  • The stock price of Astellas Pharma has shown stability and potential for growth, making it an attractive investment opportunity.

Cons

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

  • Despite positive aspects, the company operates in a highly competitive industry, which may pose challenges for sustained growth and market share.
  • Astellas Pharma's stock price has experienced fluctuations, indicating potential volatility in the market that could impact investor returns.
  • The company's price-to-earnings ratio of 28.05 and price-to-earnings-growth ratio of 2.66 may suggest that the stock is currently overvalued, potentially limiting short-term gains for investors.
  • There has been a recent increase in short interest in Astellas Pharma, which could indicate market sentiment leaning towards a bearish outlook on the stock.
  • Investors should consider the potential impact of regulatory changes or developments in the pharmaceutical industry on Astellas Pharma's operations and financial performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Astellas Pharma pros and cons to contact@marketbeat.com.

ALPMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALPMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPMY, but not buy additional shares or sell existing shares.
View ALPMY analyst ratings or view top-rated stocks.

How have ALPMY shares performed in 2024?

Astellas Pharma's stock was trading at $11.90 at the beginning of the year. Since then, ALPMY shares have decreased by 20.5% and is now trading at $9.46.
View the best growth stocks for 2024 here.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 171,800 shares, an increase of 53.1% from the March 15th total of 112,200 shares. Based on an average trading volume of 545,200 shares, the short-interest ratio is presently 0.3 days.
View Astellas Pharma's Short Interest.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) released its earnings results on Monday, February, 5th. The company reported $0.12 earnings per share (EPS) for the quarter. The business had revenue of $2.86 billion for the quarter. Astellas Pharma had a net margin of 0.08% and a trailing twelve-month return on equity of 6.39%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.34 per share and currently has a dividend yield of 3.59%.

When did Astellas Pharma's stock split?

Astellas Pharma's stock split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Astellas Pharma have any subsidiaries?
The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More
This page (OTCMKTS:ALPMY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Biden out June 13; Kamala won’t replace him?
Paradigm Press
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
Urgent alert: open this for a huge profit potential
Timothy Sykes
Options trading has suddenly become more reliable.
Eagle Publishing
A.I. is a Tidal Wave - Here’s What to Buy
Chaikin Analytics